Arden Farms are the first to use the Actiphage® blood test to test their herd of Red Deer for Johne’s...
Mycobacteria are responsible for a number of diseases including: Bovine tuberculosis, a chronic, infectious disease caused by Mycobacterium bovis (M.bovis), it can infect humans, livestock, wildlife, and exotic species and Johne's Disease or ParaTB which is a wasting disease in ruminants.
Unlike other technologies, the Actiphage test does not measure an immune response, but specifically detects the DNA extracted from live Mycobacteria present in circulating blood as a marker of disease.
PBD Biotech is currently in the process of verifying the Actiphage test for the detection of Mycobacterium bovis (bovine TB) in cattle blood.
Certification by the World Organisation for Animal Health (OIE) is required for a bTB diagnostics to become an internationally recognised diagnostic, however, Actiphage can be used as a diagnostic in England and Wales for disease management in areas of chronic disease breakdown.
These restrictions are not in place for Johne's Disease also known as MAP and PBD Biotech has launched a commercial Johne's Disease testing service.
However, Actiphage is able to detect most other mycobacterial species and has been successfully applied to samples from multiple animal species.
PBD Biotech has proof-of-concept data that the test can be applied to over 20 species, including humans, and remain open to collaboration with researchers and regulators across the globe who want to advance the science and understanding of these devastating diseases.
Actiphage and Johne's Disease or MAP
MAP testing for milk quality assurance
To use the Johne's Testing Service for blood or bulk milk do get in touch
If you are interested in using Actiphage for research use the order form or contact us
New testing service for Johne’s Disease/MAP
If you would like to know more about our testing service or to discuss the use of test kits for research do get in touch.
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom
More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB
Read MoreDelighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies
Read MoreTesting 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease
Read More